Clinical Trial Update: Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE) [Phase 2]

View source ↗

Summary

Phase 2 APPLE trial results evaluating osimertinib in EGFR T790M plasma-positive non-small cell lung cancer patients have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: NSCLC | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-10-31